Samuel Nam
Associate Director, Quality Assurance
- Role
- Associate Director, Quality Assurance at Sumitomo Pharma America, Inc.
- Location
- Marlborough, MA, US
- LinkedIn followers
- 500 followers
About Samuel Nam
Samuel is a quality professional with 25 years of experience leading drug development from discovery to commercial launch in small molecule, biologic and ADC modalities. He is currently QA lead of the Enzomenib menin inhibitor and SMP-3124 CHK1 inhibitor programs at Sumitomo Pharma. Previously, he managed product disposition at Takeda, Shire and Pfizer, and led the discovery of Indusatumab vedotin at Millennium Pharmaceuticals. His team also established the cell based potency and HCP impurity assays for Entyvio (vedolizumab). Samuel began his career at Organogenesis developing the cellular skin substitute Apligraf, and PharmaMar where he characterized Yondelis and Aplidin for IND submissions. He earned a BSc at the University of Massachusetts, Amherst and lives in the Merrimack Valley north of Boston.
Experience
Associate Director, Quality Assurance
Jan 2020 — Present · Marlborough, MA, US
Education
University of Massachusetts Amherst
Bachelor of Science, Biology
1995
Find verified contacts for anyone on LinkedIn
Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.
Free plan included · No credit card required
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.